Today: 10 April 2026
Browse Category

NASDAQ:ALNY 20 December 2025 - 13 January 2026

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam shares fell 0.1% to $370.39 Tuesday afternoon after the company projected 2026 net product revenue between $4.9 billion and $5.3 billion. Preliminary 2025 sales were disclosed at $2.987 billion. Analysts remained mostly positive but flagged possible weakness for Amvuttra next quarter. The update came as Alnylam outlined its new five-year strategy at the J.P. Morgan Healthcare Conference.
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam shares fell 6.7% to $370.91 after preliminary fourth-quarter sales for Amvuttra missed Wall Street estimates. The company reported about $827 million in Amvuttra revenue, below analyst expectations of $852 million. Alnylam set 2026 product revenue guidance at $4.9 billion to $5.3 billion and outlined a new five-year plan. Full results are due in February.
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam shares fell 6.7% to $370.91 in after-hours trading Monday after the company issued 2026 sales guidance and launched its “Alnylam 2030” plan. Preliminary Q4 sales of Amvuttra reached about $827 million, missing some estimates. Management projected 2026 net product revenue of $4.9–$5.3 billion, mostly from its TTR franchise. The company targets over 25% annual revenue growth through 2030.
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals closed up 1.87% at $407.73 Monday, its first session as a Nasdaq-100 constituent. The stock slipped 0.12% after hours. Index inclusion drove trading volume to about 1.05 million shares. Alnylam recently announced a $250 million expansion of its Massachusetts manufacturing site.
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals joined the Nasdaq-100 Index on Dec. 22, 2025, as the annual reconstitution took effect before the market opened. Shares traded near $405.60, up 1.3% from the prior close. The company recently announced a $250 million U.S. manufacturing expansion and reported strong adoption of its AMVUTTRA therapy for transthyretin amyloidosis.
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals joins the Nasdaq-100 before the U.S. market opens Dec. 22, prompting index-tracking funds to adjust positions. Shares last closed at $400.23. The company’s drug Amvuttra recently secured routine NHS use in England and Health Canada approval for ATTR cardiomyopathy. Alnylam also announced a $250 million manufacturing expansion and new FDA recognition for its technology platform.
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) closed Friday, Dec. 19, 2025, at $400.23, up 1.15% on heavy volume of 12.6 million shares, with little movement after hours. The Nasdaq-100 reconstitution takes effect before the U.S. market opens Monday, Dec. 22, adding Alnylam to the index. Friday’s session saw record derivatives expirations, amplifying trading volume.
20 December 2025

Stock Market Today

  • Infosys Share Price Live: Stock Closes at Rs 1346.2 Amid Steady Market Activity
    April 10, 2026, 12:48 AM EDT. Infosys stock closed at Rs 1346.2, reflecting strong investor interest. The company's market capitalization stands at Rs 522525.05 crore with a trading volume of 5,987,344 shares. Key financial metrics include a price-to-earnings (P/E) ratio of 18.68, indicating how much investors are willing to pay per rupee of earnings, and earnings per share (EPS) of 68.99. These figures highlight Infosys's robust profitability and market valuation as of 10:08 AM IST on April 10, 2026. Investors are closely monitoring both fundamental and technical indicators amid ongoing market developments affecting the stock's performance.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 12:55 AM EDT Infosys Share Price Live: Stock Closes at Rs 1346.2 Amid Steady Market Activity April 10, 2026, 12:48 AM EDT. Infosys stock closed at Rs 1346.2, reflecting strong investor interest. The company's market capitalization stands at Rs 522525.05 crore with a trading volume of 5,987,344 shares. Key financial metrics include a price-to-earnings (P/E) ratio of 18.68, indicating how much investors are willing to pay per rupee of earnings, and earnings per share (EPS) of 68.99. These figures highlight Infosys's robust profitability and market valuation as of
MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

MARA Holdings Stock Rises Even After Target Cut as Bitcoin Miner Leans Harder Into AI

9 April 2026
MARA Holdings shares rose 1.7% to $9.67 Thursday despite Cantor Fitzgerald cutting its price target to $10. The company recently sold 15,133 bitcoin for $1.1 billion and agreed to repurchase $1 billion in convertible notes at a discount. MARA is expanding into AI and cloud infrastructure, but fourth-quarter revenue fell 6% and it posted a $1.7 billion net loss.
CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

CoreWeave secures fresh $21 billion Meta AI deal as debt push raises stakes

9 April 2026
Meta Platforms signed a new $21 billion deal with CoreWeave for AI cloud computing capacity through 2032, according to a securities filing. CoreWeave shares rose 3.4% in after-hours trading. The agreement adds to a $14.2 billion commitment disclosed last September. CoreWeave also launched $3 billion in convertible notes and upsized a senior-notes deal to $1.75 billion.
Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

Tesla Revives Cheaper EV Push With New Compact SUV as Sales Pressure Builds

9 April 2026
Tesla is developing a lower-cost compact SUV, with initial production planned for Shanghai, Reuters reported Thursday. The company built 408,386 vehicles and delivered 358,023 in the first quarter, leaving its widest gap in at least four years. Reuters said the new SUV likely will not reach production this year. Tesla did not respond to questions about the project.
NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

NIO ES9 Price Starts at 528,000 Yuan as Flagship SUV Bet Faces China EV Slump

9 April 2026
NIO opened pre-orders for its ES9 flagship SUV Thursday, pricing it at 528,000 yuan with battery or 420,000 yuan under its Battery-as-a-Service plan. March deliveries rose 136% year-on-year, but NIO’s U.S. shares fell 4.9% after the announcement. The ES9 enters a shrinking premium SUV market in China, competing with Li Auto and Aito. CEO William Li warned chip shortages could add up to 10,000 yuan per vehicle.
Go toTop